Deferasirox for the Treatment of Chronic Iron Overload in Transfusional Hemosiderosis
ByGeorge Shashaty, MD,Raymond Frankewich, PhD,Tamal Chakraborti, PhD,Jasti Choudary, PhD,Suliman Al-fayoumi, PhD,Alice Kacuba, RN, MSN,Sonia Castillo, PhD,Kathy Robie-suh, MD, PhD,Dwaine Rieves, MD,Karen Weiss, MD,Richard Pazdur, MD
Published: | Updated:
This report describes the Food and Drug Administration's review of data and analyses leading to the approval of the oral iron chelator, deferasirox for the treatment of chronic iron overload due to transfusional hemosiderosis.